LTS - Ladenburg Thalmann Financial Services Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
3.4900
-0.0100 (-0.29%)
As of 4:00PM EST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.5000
Open3.4900
Bid0.0000 x 317000
Ask0.0000 x 42300
Day's Range3.4900 - 3.5000
52 Week Range1.8100 - 3.5100
Volume756,345
Avg. Volume0
Market Cap520.607M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 08, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Moody's

      Polski Koncern Naftowy ORLEN S.A. -- Moody's announces completion of a periodic review of ratings of Polski Koncern Naftowy ORLEN S.A.

      Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Polski Koncern Naftowy ORLEN S.A. Frankfurt am Main, May 27, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Polski Koncern Naftowy ORLEN S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

    • Advisor Group and Securities America Announce Recruitment of Hybrid Advisory Firm with More Than $120 Million in Total Client Assets
      Business Wire

      Advisor Group and Securities America Announce Recruitment of Hybrid Advisory Firm with More Than $120 Million in Total Client Assets

      Securities America has recruited 20/20 Wealth Management Group. The Alabama-based firm has more than $120M in total client assets.

    • GlobeNewswire

      Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

      Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the closing of its previously announced underwritten public offering, with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase one share of common stock with an exercise price of $1.15 per share.

    • Is Ladenburg Thalmann (LTS) a Great Value Stock Right Now?
      Zacks

      Is Ladenburg Thalmann (LTS) a Great Value Stock Right Now?

      Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

    • GlobeNewswire

      Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

      Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase one share of common stock with an exercise price of $1.15 per share.

    • GlobeNewswire

      Oxford Lane Capital Corp. Prices Preferred Stock Offering

      Oxford Lane Capital Corp. (the “Company”) (Nasdaq GS: OXLC, OXLCO and OXLCM) today announced that it has priced an underwritten public offering of 3,500,000 shares of its newly designated 6.25% Series 2027 Term Preferred Shares (the “Preferred Stock”) at a public offering price of $25 per share, raising $87.5 million in gross proceeds. The Company has also granted the underwriters a 30-day option to purchase up to 525,000 additional shares of Preferred Stock on the same terms and conditions to cover over-allotments, if any. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), and BB&T Capital Markets, a division of BB&T Securities, LLC, are acting as the joint book-running managers for the offering.

    • GlobeNewswire

      Oxford Lane Capital Corp. Announces Preferred Stock Offering

      Oxford Lane Capital Corp. (the “Company”) (NasdaqGS: OXLC, OXLCO and OXLCM) today announced that it plans to offer shares of its newly designated Series 2027 Term Preferred Shares (the “Preferred Stock”) in an underwritten public offering. The public offering price and other terms of the Preferred Stock are to be determined by negotiations between the Company and the underwriters. The Company also plans to grant the underwriters a 30-day option to purchase additional shares of Preferred Stock on the same terms and conditions to cover over-allotments, if any.

    • GlobeNewswire

      CHF Solutions, Inc. Announces Pricing of $8.4 Million Underwritten Public Offering

      CHF Solutions, Inc. (CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $8.4 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The offering is comprised of (1) 3,755,458 Class A Units, priced at a public offering price of $0.55 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.55 per share that expires on the fifth anniversary of the date of issuance, and (2) 11,517,269 Class B Units, priced at a public offering price of $0.55 per unit, with each unit consisting of one share of Series H convertible preferred stock, convertible into one share of common stock, and a warrant to purchase one share of common stock with an exercise price of $0.55 per share.

    • Is Ladenburg Thalmann (LTS) Stock Undervalued Right Now?
      Zacks

      Is Ladenburg Thalmann (LTS) Stock Undervalued Right Now?

      Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

    • GlobeNewswire

      LTS, KEM, WMGI, and WLH SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

      WILMINGTON, Del., Jan. 17, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Ladenburg Thalmann Financial Services Inc. (NYSE AMERICAN: LTS) regarding.

    • Moody's

      Advisor Group Holdings, Inc. -- Moody's Confirms Advisor Group's Ratings (B2 Corporate Family)

      This action concludes the review for downgrade, initiated on 19 November 2019, that followed Advisor Group's announcement of its planned acquisition of publicly-held Ladenburg Thalmann Financial Services Inc. (Ladenburg Thalmann, unrated) for a $1.3 billion enterprise value (including common stock, preferred stock and outstanding debt). Moody's has assigned a B1 rating to Advisor Group's proposed $775 million senior secured notes that it intends to issue to help fund the acquisition. Advisor Group expects to complete the acquisition in the first half of 2020, subject to Ladenburg Thalmann's shareholders' approval and regulatory approvals.

    • ACCESSWIRE

      SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ladenburg Thalmann Financial Services Inc. (LTS)

      NEW YORK, NY / ACCESSWIRE / January 6, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Ladenburg Thalmann Financial Services Inc. (" Ladenburg ...

    • ACCESSWIRE

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - CBB, AXE, LTS

      NEW YORK, NY / ACCESSWIRE / December 24, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cincinnati Bell Inc. (NYSE:CBB) The investigation ...

    • Hedge Funds Are Warming Up To Ladenburg Thalmann Financial Services (LTS)
      Insider Monkey

      Hedge Funds Are Warming Up To Ladenburg Thalmann Financial Services (LTS)

      Is Ladenburg Thalmann Financial Services (NYSE:LTS) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The […]

    • Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
      CNW Group

      Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

      SEATTLE and VANCOUVER, British Columbia , Dec. 19, 2019 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million , which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering was comprised of Class A units, priced at a public offering price of $0.60 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $0.60 per share, and Class B units, priced at a public offering price of $999.60 per unit, with each unit comprised of one share of Series B preferred stock, which is convertible into 1,666 shares of common stock, and a five-year warrant to purchase 1,666 shares of common stock, also with an exercise price of $0.60 per share.

    • GlobeNewswire

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – TCBI, WLH, AXE, LTS

      NEW YORK, Dec. 16, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Texas Capital Bancshares, Inc. (NASDAQ:.

    • GlobeNewswire

      Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

      The offering included participation from new and existing investors, and together with the concurrent private placement raised gross proceeds of approximately $70 million, before deducting underwriting discounts and commissions, placement agent fees and estimated offering expenses payable by the Company. Craig-Hallum Capital Group LLC acted as co-manager for the offering. Concurrently with the completion of the public offering, the Company sold to certain investors in a private placement, a number of shares of convertible preferred stock equal to an aggregate purchase price of up to $30 million, at a conversion price of $1.25 per share.

    • Moody's

      Polski Koncern Naftowy ORLEN S.A. -- Moody's changes outlook to negative and affirms PKN ORLEN's Baa2 rating

      Moody's Investors Service ("Moodys") has today affirmed the issuer rating of Polski Koncern Naftowy ORLEN S.A. ("PKN ORLEN" or "company") at Baa2 and also affirmed the baseline credit assessment (BCA) at baa3. Concurrently, Moody's has also affirmed at Baa2 the rating of the EUR 500 million due 2021 and EUR 750 million due 2023 senior unsecured bonds issued by ORLEN Capital AB (publ) and guaranteed by PKN ORLEN.

    • GlobeNewswire

      Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

      The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 4,200,000 shares of common stock.

    • GlobeNewswire

      Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

      The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 4,200,000 shares of common stock.

    • GlobeNewswire

      Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

      All of the shares in the offering are to be sold by Marinus. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares to be issued and sold in the public offering. Concurrently with the completion of the public offering, the Company expects to sell to certain investors in a private placement, a number of shares of convertible preferred stock equal to an aggregate purchase price of up to approximately $30 million, at a price equal to the public offering price.

    • ACCESSWIRE

      SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Sale of these Companies is Fair to Shareholders - LTS, CBPX, TECD

      NEW YORK, NY / ACCESSWIRE / November 25, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ladenburg Thalmann Financial Services Inc. (NYSE:LTS) ...

    • GlobeNewswire

      KEM, LTS, CARO, and CARB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

      WILMINGTON, Del., Nov. 24, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: KEMET Corporation (NYSE: KEM) regarding possible breaches of fiduciary duties.